A comparison of the effects of aggressive dose and conventional dose atorvastatin applications on IL-6 and NO levels in patients with acute myocardial infarction

Basit Öğe Kaydı
dc.contributor.authorBasarali, Mustafa Kemal
dc.contributor.authorBuyukbas, Sadik
dc.contributor.authorYazar, Hayrullah
dc.contributor.authorKiyici, Aysel
dc.contributor.authorKayrak, Mehmet
dc.contributor.authorUlgen, Siddik
dc.date.accessioned2020-03-26T18:08:10Z
dc.date.available2020-03-26T18:08:10Z
dc.date.issued2011
dc.departmentSelçuk Üniversitesien_US
dc.description.abstractHigh dose statin medication in acute coronary syndrome cases is a therapy which lowers mortality and morbidity rates. Interleukin-6 (IL-6) is produced in higher amounts in acute myocardial infarction (MI) and facilitates myocardial damage. However, secretion of nitric oxide (NO) is depleted. We aimed to compare the effects of conventional dose (10-40 mg/day) and aggressive dose (80 mg/day) atorvastatin medications on IL-6 and NO levels in patients with primary percutaneous transluminal coronary angioplasty (PTCA) intervention after acute MI. 50 patients (8 females, 42 males) with the diagnosis of acute MI with ST segment elevation enrolled to the study. Primary PTCA intervention was performed on these patients and consequently either conventional dose (10 to 40 mg/day) or aggressive dose (80 mg/day) atorvastatin medications were given to the patients. Three months later, plasma IL-6 and NO levels were determined and alterations in the groups were evaluated. IL-6 levels decreased from 24.34 +/- 12.04 to 11.40 +/- 5.79 pg/ml and from 29.62 +/- 17.38 to 12.51 +/- 8.95 pg/ml in conventional dose and aggressive dose regimens respectively (p<0.001). However, NO concentrations increased from 22.90 +/- 8.24 to 31.70 +/- 7.56 mu M in conventional dose and from 19.37 +/- 5.60 mu M to 34.15 +/- 9.60 mu M in aggressive dose groups (p < 0.001). The effects of aggressive dose atorvastatin medication on IL-6 and NO levels were similar to conventional dose application in cases with ST segment elevation acute MI.en_US
dc.description.sponsorshipScientific Investigations and Projects Coordination of Selcuk UniversitySelcuk University [BAP06102008]en_US
dc.description.sponsorshipThe research was funded by Scientific Investigations and Projects Coordination of Selcuk University grant (Project Number: BAP06102008).en_US
dc.identifier.endpage1602en_US
dc.identifier.issn1996-0816en_US
dc.identifier.issue13en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage1598en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12395/26043
dc.identifier.volume5en_US
dc.identifier.wosWOS:000299643800006en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherACADEMIC JOURNALSen_US
dc.relation.ispartofAFRICAN JOURNAL OF PHARMACY AND PHARMACOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.selcuk20240510_oaigen_US
dc.subjectAtorvastatinen_US
dc.subjectinterleukin-6en_US
dc.subjectnitric oxideen_US
dc.subjectmyocardial infarctionen_US
dc.titleA comparison of the effects of aggressive dose and conventional dose atorvastatin applications on IL-6 and NO levels in patients with acute myocardial infarctionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu